Loading data for IMCR — first visit, this takes a few seconds.
Immunocore Holdings plc (IMCR)
NasdaqGS: IMCR
· Real-Time Price · USD
36.13
-1.44 (-3.83%)
At close: Sep 04, 2026, 8:00 PM
The price, the headline numbers and the latest news, in one place.
Immunocore Holdings plc (IMCR) Stock Price, Analysis & Data
No data available
| Bid | 26.72 |
| Market Cap | 1.86B |
| Revenue (ttm) | 431M |
| Net Income (ttm) | -18.1M |
| 0.74 | |
| -0.36 | |
| n/a | |
| -48.11 | |
| P/B (ttm) | 4.43 |
| P/S (ttm) | 4.32 |
| Earnings Date | Nov 6, 2025 |
| Ask | 36.2 |
| Volume | 231,712 |
| Avg. Volume (20D) | 513,900 |
| Open | 37.24 |
| Previous Close | 37.57 |
| Day's Range | 35.98 - 37.43 |
| 52-Week Range | 27.55 - 40.72 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About IMCR
Immunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internationally. The company offers KIMMTRAK for the treatment of unresectable or metastatic uveal melanoma. It also develops oncology programs, including tebentafusp which is in Phase 3 clinical trial for the ...
Industry Biotechnology
Sector Healthcare
IPO Date Feb 5, 2021
Employees 524
Stock Exchange NasdaqGS
Ticker Symbol IMCR
Website https://www.immunocore.com
Financial Performance
In 2025, Immunocore s plc's revenue was 400.02M, an increase of 28.95% compared to the previous year's 310.2M. Earnings were -35.51M, a decrease of -30.48%.
Financial StatementsEarnings Surprise
Immunocore s plc has released their quarterly earnings on Aug 6, 2026:
- Revenue of $115.93M misses estimates by $0, with 18.34% YoY growth.
- EPS of -0.02 misses estimates by -0.04, with -120.00% YoY decline.
Immunocore Holdings plc is scheduled to release its earnings on Nov 6, 2025, before market opens.
Analysts project revenue of ... Upgrade
Analysts project revenue of ... Upgrade
Page 1 of 2